Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02221960
Recruitment Status : Completed
First Posted : August 21, 2014
Last Update Posted : March 13, 2019
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC

Brief Summary:
To evaluate MEDI6383 when given alone or together with MEDI4736 in adult subjects with recurrent or metastatic solid tumors.

Condition or disease Intervention/treatment Phase
Recurrent or Metastatic Solid Tumors Biological: MEDI6383 Biological: MEDI6383 and MEDI4736 Phase 1

Detailed Description:
This is a Phase 1, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and antitumor activity of MEDI6383 alone and in combination with MEDI4736 in adult subjects with recurrent or metastatic solid tumors.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Actual Study Start Date : September 15, 2014
Actual Primary Completion Date : July 3, 2017
Actual Study Completion Date : July 3, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Durvalumab

Arm Intervention/treatment
Experimental: Monotherapy Arm
MEDI6383
Biological: MEDI6383
Subjects will receive MEDI6383 until disease progression or adverse event.

Experimental: Combination Arm
MEDI6383 and MEDI4736
Biological: MEDI6383 and MEDI4736
Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.




Primary Outcome Measures :
  1. Safety [ Time Frame: From time of informed consent through 12 weeks after last dose of investigational product ]
    Primary endpoint will be the number (%) of subjects with adverse events and serious adverse events.


Secondary Outcome Measures :
  1. Preliminary Antitumor Activity [ Time Frame: Duration of Study ]
    The endpoints for assessment of antitumor activity include objective response (OR), disease control (DC), duration of response (DoR), progression-free survival (PFS), and 3-year overall survival (OS)

  2. Pharmacokinetics of MEDI6383 or MEDI6383/MEDI4736 [ Time Frame: From time of informed consent through 12 weeks after last dose of investigational product ]
    When MEDI6383 is administered alone, the endpoints for assessment of PK of MEDI6383 include individual subject MEDI6383 concentrations in serum at different time points after MEDI6383 administration. When MEDI6383 is administered together with MEDI4736, the endpoints for assessment of PK of MEDI6383 and MEDI4736 include individual subject MEDI6383 and MEDI4736 concentrations in serum at different time points after MEDI6383 and MEDI4736 administration. PK Parameters that may be modeled may include Cmax, Area Under the concentration-time curve, Clearance, and terminal half-live.

  3. Biomarker Activity [ Time Frame: From time of informed consent through 12 weeks after last dose of investigational product ]
    The endpoints for assessment of pharmacodynamic activity include immunohistochemistry of tumor biopsies and assessment of tumor-infiltrating lymphocyte phenotypic markers

  4. Immunogenicity [ Time Frame: From time of informed consent through 12 weeks after last dose of investigational product ]
    The endpoint for for the assessment of immunogenicity will include the number and percentage of subjects that develop anti-drug antibodies.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects; age ≥ 18
  2. Written informed consent must be obtained
  3. Subjects must meet the following criteria:

    1. Have recurrent or metastatic solid tumors
    2. Must have received and have progressed, are refractory, or are intolerant to standard therapy appropriate for the specific tumor type. Subjects should not have received more than 5 prior lines of therapy for recurrent or metastatic disease including both standards of care and investigational therapies
  4. Subjects must have at least 1 lesion
  5. Subjects must consent to provide archived tumor specimens and / or tumor biopsy for correlative biomarker studies.
  6. Eastern Cooperative Oncology Group performance score of 0 or 1
  7. In the opinion of the invesgator likely to complete ≥ 8 weeks of treatment.
  8. Adequate organ function as determined by:

    i. Absolute neutrophil count ≥ 1.5 x 109/L (1,500/mm3) ii.Platelet count ≥ 100 x 109/L (100,000/mm3) iii.Hemoglobin ≥ 9.0 g/dL within first 2 weeks prior to first dose of investigational product iv.Calculated creatinine clearance* (CrCl) or 24 hour urine CrCl > 50 mL/min v.Total bilirubin ≤ 1.5× ULN; for subjects with documented/suspected Gilbert's disease, bilirubin ≤ 3× ULN vi.Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5× ULN vii.Serum Electrolytes within normal limits

  9. Females of childbearing potential who are sexually active with a nonsterilized male partner must use 2 methods of highly effective contraception from screening, and must agree to continue using such precautions for 90 days after the final dose of investigational product; 10) Nonsterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from Day 1 through 90 days after receipt of the final dose of investigational product

Exclusion Criteria:

  1. Prior treatment with TNFRSF agonists including OX40, CD27, CD137 (4-1BB), CD357 (GITR) .
  2. Subjects who have received prior therapy with regimens containing CTLA-4, PDL-1, or PD-1 antagonists are NOT permitted to enroll unless all of the following apply:

    • Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy
    • All AEs while receiving prior immunotherapy must have resolved to ≤ Grade 1 or baseline prior to screening for this study.
  3. Must not have experienced a ≥ Grade 3 AE or neurologic or ocular AE of any grade while receiving prior immunotherapy
  4. History of severe allergic reactions to any unknown allergens or any components of the study drug formulations
  5. Active or prior documented autoimmune disease within the past 2 years.
  6. Untreated central nervous system metastatic disease l
  7. Concurrent enrollment in another clinical study, unless it is an observational (non interventional) clinical study or the follow-up period of an interventional study
  8. Receipt of anticancer therapy within 28 days prior to the first dose of Investigational Product
  9. Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment.
  10. Unresolved toxicities from prior anticancer therapy
  11. Systemic anticoagulation or daily aspirin dose exceeding 325 mg per day
  12. Current or prior use of immunosuppressive medication within 14 days prior to the first dose of MEDI6383. )
  13. History of primary immunodeficiency, solid organ transplantation, or tuberculosis
  14. True positive test results for human immunodeficiency virus (HIV) or hepatitis B or C
  15. Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products )
  16. Pregnant or breastfeeding women
  17. Major surgery (as defined by the investigator) within 4 weeks prior to first dose of MEDI6383 or still recovering from prior surgery. Local surgery of isolated lesions for palliative intent is acceptable
  18. Other invasive malignancy within 2 years

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02221960


Locations
Layout table for location information
United States, California
Research Site
La Jolla, California, United States, 92093
United States, Connecticut
Research Site
New Haven, Connecticut, United States, 06520
United States, District of Columbia
Research Site
Washington, District of Columbia, United States, 20007
United States, Illinois
Research Site
Chicago, Illinois, United States, 60611
United States, New York
Research Site
New York, New York, United States, 10065
United States, Oregon
Research Site
Portland, Oregon, United States, 97213
United States, Tennessee
Research Site
Nashville, Tennessee, United States, 37203
Australia
Research Site
Parkville, Australia, 3052
Sponsors and Collaborators
MedImmune LLC
Investigators
Layout table for investigator information
Study Director: Medimmune Medimmune MedImmune LLC

Layout table for additonal information
Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT02221960     History of Changes
Other Study ID Numbers: D6050C00001
First Posted: August 21, 2014    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019
Keywords provided by MedImmune LLC:
Recurrent or metastatic solid tumors, MEDI6383, OX40
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Durvalumab
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs